Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used in phase 2.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek: dorosły pacjent (zgodnie z wymogami kraju)
- •Potwierdzony w badaniu genu RET (z próbki tkanki lub krwi)
- •Zaawansowany nowotwór litej
- •Funkcjonowanie codzienne: samodzielnie lub z minimalną pomocą
- •Wystarczająco dobre wyniki badań krwi i funkcji wątroby i nerek
- •Nowotwór możliwy do zmierzenia lub oceny według międzynarodowych standardów
- •Jeśli są przerzuty do mózgu: bez objawów
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 19, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (29)
Chao Family Comprehensive Cancer Center
Orange, United States
Stanford Cancer Center
Stanford, United States
Massachusetts General Hospital
Boston, United States
Henry Ford Hospital
Detroit, United States
START Midwest - Cancer & Hematology Centers of Western Michigan
Grand Rapids, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
New York, United States
Memorial Sloan Kettering Cancer Center
New York, United States
The Sarah Cannon Research Institute/Tennessee Oncology
Nashville, United States
The University of Texas M. D. Anderson Cancer Center
Houston, United States
Cabrini Hospital
Malvern, Australia
Linear Clinical Research
Nedlands, Australia
GenesisCare North Shore
Saint Leonards, Australia
National Cancer Center Hospital East
Kashiwa-shi, Japan
Tohoku University Hospital
Sendai, Japan
Okayama University Hospital
Okayama, Japan
Kansai Medical University Hospital
Hirakata-shi, Japan
Osaka International Cancer Institute
Osaka, Japan
Shizuoka Cancer Center
Shizuoka, Japan
National Cancer Center Hospital
Chuo-ku, Japan
The Cancer Institute Hospital of JFCR
Koto-ku, Japan
Aichi Cancer Center
Aichi, Japan
National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan
Kanagawa Cancer Center
Kanagawa, Japan
Kurashiki Central Hospital
Okayama, Japan
Kindai University Hospital
Osaka, Japan
Seoul National University Bundang Hospital
Seongnam, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea
Trial contact
Kazuo Koba
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/20/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.